Controlled-release and stratified cyclodextrin inclusion complex vehicles
AssigneeCZAP Research and Development LLC
InventorAl Czap
Life of this patent
Estimating the term…
Abstract
The invention provides cyclodextrin inclusion complex delivery vehicles, in which the cyclodextrin inclusion complex is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases the guest molecule from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of medicaments, food ingredients, medical food ingredients, nutritional supplement ingredients, dietary supplement ingredients, herbicides, insecticides, fungicides, animal repellents, pheromones, plant growth regulators, fragrances, fabrics or packaging materials.
Claims12
A cyclodextrin inclusion complex delivery vehicle formulated for oral delivery to a human subject in need thereof, comprising:
- a cyclodextrin having a cavity;
- N-acetylcysteine and acetaminophen at least partially retained as stacked guest molecules within the cavity of the cyclodextrin, forming a cyclodextrin inclusion complex;
- a pharmaceutically acceptable carrier for oral delivery of the cyclodextrin inclusion complex, wherein the N-acetylcysteine and acetaminophen are stably retained in the cyclodextrin inclusion complex within the pharmaceutically acceptable carrier;
- and,
- an enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin retaining the N-acetylcysteine and acetaminophen, wherein the enzyme is co-formulated with the cyclodextrin inclusion complex so that the cyclodextrin-degrading activity is activated on oral delivery of the vehicle to a human subject so as to release the one or more guest molecules from the cyclodextrin cavity.
A method of formulating a cyclodextrin inclusion complex delivery vehicle for oral delivery to a human subject in need thereof, comprising:
- providing a cyclodextrin having a cavity;
- admixing the cyclodextrin with N-acetylcysteine and acetaminophen so that N-acetylcysteine and acetaminophen are at least partially retained as stacked guest molecules within the cavity of the cyclodextrin, forming a cyclodextrin inclusion complex;
- admixing the cyclodextrin inclusion complex with a pharmaceutically acceptable carrier for oral delivery, wherein the N-acetylcysteine and acetaminophen are stably retained by the cyclodextrin inclusion complex within the pharmaceutically acceptable carrier;
- and,
- admixing an enzyme with the cyclodextrin inclusion complex and the pharmaceutically acceptable carrier, the enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin retaining the cyclodextrin inclusion complex, wherein the enzyme is co-formulated with the cyclodextrin inclusion complex so that the cyclodextrin-degrading activity is activated on oral delivery of the vehicle to a human subject so as to release the guest molecule from the cyclodextrin cavity.
Dependencies are inferred from the claim text.